Date: 2016-03-07
Type of information: Initiation of the trial
phase: 1
Announcement: initiation of the trial
Company: Vical (USA - CA)
Product: VL-2397 (cyclo{-Asn-Leu-d-Phe-Al[(N5-acetyl-N5-hydroxy-Orn)-(N5-acetyl-N5-hydroxy-Orn)-(N5-hydroxy-Orn)]-} . Al(III))
Action
mechanism: antifungal agent. In preclinical studies to date, VL-2397 has demonstrated both faster fungicidal activity than marketed drugs and activity against azole-resistant fungal pathogens. VL-2397 was initially developed by Astellas Pharma. In March 2015, Astellas granted Vical an exclusive worldwide license to develop and commercialize VL-2397.
Disease: invasive aspergillosis
Therapeutic area: Infectious diseases
Country: USA
Trial details:
Latest
news: * On March 7, 2016, Vical announced the initiation of a Phase 1 clinical trial of itsnovel antifungal, VL-2397. The randomized, double-blind trial will evaluate safety, tolerability and pharmacokinetics of VL-2397 at single and multiple ascending doses in healthy volunteers at a single U.S. clinical site.
Vical intends to develop VL-2397 as a treatment for invasive aspergillosis and for infections caused by other pathogenic fungi.
